IDH1 and central nervous system cancer: The heterozygous R132H mutation in IDH1 accounts for 95% of IDH1/2 mutations in gliomas [11], however heterozygous mutations also occur in the analogous amino acid of IDH2 (R172), including R172G, R172K, and R172M [4, 12].